Medical Oncology最新文献

Incidence of lymphedema related to various cancers 与各种癌症有关的淋巴水肿发生率

IF 3.4 4区医学

Medical Oncology Pub Date : 2024-09-17 DOI: 10.1007/s12032-024-02441-2

Marie-Eve Letellier, Marize Ibrahim, Anna Towers, Geneviève Chaput

{"title":"Incidence of lymphedema related to various cancers","authors":"Marie-Eve Letellier, Marize Ibrahim, Anna Towers, Geneviève Chaput","doi":"10.1007/s12032-024-02441-2","DOIUrl":"https://doi.org/10.1007/s12032-024-02441-2","url":null,"abstract":"Cancer-related lymphedema (CRL) lacks internationally accepted definition and diagnostic criteria. The accurate incidence of CRL is therefore a challenge and the condition is likely underreported. Patients treated for cancer can develop CRL as a result of surgery, chemotherapy, and/or radiotherapy, which can lead to considerable psychosocial and physical morbidity, and decreased quality of life. Determining CRL incidence is crucial to inform care access and resource allocation, to best support patients affected by this lifelong condition. This review aimed to provide the latest CRL incidence estimates. Using four core databases (MEDLINE, Embase, Web of Science Core Collection, Cochrane Library), a literature search was performed to capture publications dated between 2015 and 2023. A total of 48 articles (33 prospective studies, 15 systematic reviews) met inclusion criteria, providing a sample size of 234,079 cancer patients. Findings revealed CRL incidence across cancer types varied, reported 2–74% in breast, 8–45% in gynecological and urological, 71–90% in head and neck and 2–29% in melanoma cancers. CRL incidence varied between 3 and 21% in preventative lymphedema surgery patients. Projected increases in cancer incidence and improved survival rates are expected to further escalate CRL incidence. Healthcare systems and professionals alike must therefore prepare to meet the growing needs of CRL patients.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review Sirt1/Nrf2通路是化疗诱发心脏毒性药物治疗的关键因素：微型综述

IF 3.4 4区医学

Medical Oncology Pub Date : 2024-09-11 DOI: 10.1007/s12032-024-02494-3

Suleiman Ibrahim Shelash Mohammad, Asokan Vasudevan, Felix Oghenemaro Enwa, Jaya Bansal, Mamata Chahar, Mamdouh Eldesoqui, Muhammad Ikram Ullah, Zhanna R. Gardanova, Hanen Mahmod Hulail, Ahmed Hussein Zwamel

引用次数: 0

Lipid metabolism reprogramming in renal cell carcinomas. 肾细胞癌中的脂质代谢重编程。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-09-06 DOI: 10.1007/s12032-024-02484-5

Mustafa Khalid Abduljabbar, Mohammed Merza, Abdulqader Aziz, Soumya V Menon, Mandeep Kaur, Zafar Aminov, Safia Obaidur Rab, Ahmed Hjazi, Yasser Fakri Mustafa, Benien C Gabel

{"title":"Lipid metabolism reprogramming in renal cell carcinomas.","authors":"Mustafa Khalid Abduljabbar, Mohammed Merza, Abdulqader Aziz, Soumya V Menon, Mandeep Kaur, Zafar Aminov, Safia Obaidur Rab, Ahmed Hjazi, Yasser Fakri Mustafa, Benien C Gabel","doi":"10.1007/s12032-024-02484-5","DOIUrl":"https://doi.org/10.1007/s12032-024-02484-5","url":null,"abstract":"This study investigates the intricate mechanisms underlying the correlation between elevated consumption of harmful fats and the onset of kidney malignancies. The rise in global obesity rates has been accompanied by an increased prevalence of renal cancers, prompting an exploration into the molecular pathways and biological processes linking these phenomena. Through an extensive review of current literature and clinical studies, we identify potential key factors contributing to the carcinogenic influence of harmful fats on renal tissues. Our analysis highlights the role of adipose tissue-derived factors, inflammatory mediators, and lipid metabolism dysregulation in fostering a microenvironment conducive to renal tumorigenesis. Furthermore, we delve into the impact of harmful fats on signaling pathways associated with cell proliferation, apoptosis evasion, and angiogenesis within the renal parenchyma. This review underscores the importance of elucidating the molecular intricacies linking lipid metabolism and kidney malignancies, offering a foundation for future research and the development of targeted preventive and therapeutic interventions. The findings discussed herein contribute to our understanding of the complex relationship between lipid mediators and renal cancer, providing a basis for public health strategies aimed at mitigating the impact of harmful fats on kidney health.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Turning the tide: pembrolizumab's triumph in adjuvant RCC therapy. 扭转乾坤：pembrolizumab 在 RCC 辅助治疗中的胜利。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-09-05 DOI: 10.1007/s12032-024-02486-3

Fouad Attieh, Marc Boutros, Hampig Raphaël Kourie, Mervat Mahrous

{"title":"Turning the tide: pembrolizumab's triumph in adjuvant RCC therapy.","authors":"Fouad Attieh, Marc Boutros, Hampig Raphaël Kourie, Mervat Mahrous","doi":"10.1007/s12032-024-02486-3","DOIUrl":"https://doi.org/10.1007/s12032-024-02486-3","url":null,"abstract":"In recent years, kidney cancer has shown an increased worldwide incidence of more than 400 000 novel cases annually. Although more than half of patients are diagnosed at a localised stage, this disease presents a high-risk of relapse after surgery. Thus, there is a need for adjuvant therapy post-resection to reduce cancer recurrence and prolong disease-free and overall survival. Thorough investigation of adjuvant drugs for renal cell carcinoma (RCC) has shown little promise in the last fifty years, with no recorded overall survival benefits. This was the case until pembrolizumab, an immune checkpoint inhibitor, was introduced into the adjuvant RCC space through the KEYNOTE-564 trial. The adjuvant administration of this novel anti-PD-1 drug demonstrated a significant overall survival benefit which has led to an update in the current treatment guidelines of RCC. This substantial change in the standard of care also caused an investigation of possible treatment combinations and an adoption of innovative predictive biomarkers. In this review, we will present the evolution of past adjuvant ICI trials for the treatment of RCC, the implications of pembrolizumab's overall survival benefits and a discussion of future directions concerning new RCC drug trials and liquid biopsy-based biomarkers.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of IL-22 in cancer. IL-22 在癌症中的作用

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-09-05 DOI: 10.1007/s12032-024-02481-8

Zachary E Hunzeker, Lei Zhao, Austin M Kim, Jacob M Parker, Ziwen Zhu, Huaping Xiao, Qian Bai, Mark R Wakefield, Yujiang Fang

引用次数: 0

Current diagnostic and quantitative techniques in the field of lymphedema management: a critical review. 当前淋巴水肿管理领域的诊断和定量技术：评论性综述。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-09-05 DOI: 10.1007/s12032-024-02472-9

Mary Vargo, Melissa Aldrich, Paula Donahue, Emily Iker, Louise Koelmeyer, Rachelle Crescenzi, Andrea Cheville

{"title":"Current diagnostic and quantitative techniques in the field of lymphedema management: a critical review.","authors":"Mary Vargo, Melissa Aldrich, Paula Donahue, Emily Iker, Louise Koelmeyer, Rachelle Crescenzi, Andrea Cheville","doi":"10.1007/s12032-024-02472-9","DOIUrl":"10.1007/s12032-024-02472-9","url":null,"abstract":"Lymphedema evaluation entails multifaceted considerations for which options continue to evolve and emerge. This paper provides a critical review of the current status of diagnostic and quantitative measures for lymphedema, from traditional and novel bedside assessment tools for volumetric and fluid assessment, to advanced imaging modalities. Modalities are contrasted with regard to empirical support and feasibility of clinical implementation. The manuscript proposes a grid framework for comparing the ability of each modality to quantify specific lymphedema characteristics, including distribution, dysmorphism, tissue composition and fluid content, lymphatic anatomy and function, metaplasia, clinical symptoms, and quality of life and function. This review additionally applies a similar framework approach to consider how well assessment tools support important clinical needs, including: (1) screening, (2) diagnosis and differential diagnosis, (3) individualization of treatment, and (4) monitoring treatment response. The framework highlights which clinical needs are served by an abundance of assessment tools and identifies others that have problematically few. The framework clarifies which tools have greater or lesser empirical support. The framework is designed to assist stakeholders in selecting appropriate diagnostic and surveillance modalities, gauging levels of confidence when applying tools to specific clinical needs, elucidating overarching patterns of diagnostic and quantitative strengths and weaknesses, and informing future investigation.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology. 免疫毒素工程的进展：现代肿瘤学的精准治疗策略。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-09-04 DOI: 10.1007/s12032-024-02478-3

Akbar Oghalaie, Mahmoud Eshagh Hosseini, Mohammad Hosseininejad-Chafi, Zohre Eftekhari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht

{"title":"Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology.","authors":"Akbar Oghalaie, Mahmoud Eshagh Hosseini, Mohammad Hosseininejad-Chafi, Zohre Eftekhari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht","doi":"10.1007/s12032-024-02478-3","DOIUrl":"https://doi.org/10.1007/s12032-024-02478-3","url":null,"abstract":"Immunotoxins (ITs) are specialized therapeutic agents designed for targeted treatment, particularly in cancer therapy. They consist of a monoclonal antibody or antibody fragment linked to a potent cytotoxic agent, such as bacterial- or plant-derived toxins like diphtheria toxin, ricin, or pseudomonas exotoxin. The monoclonal antibody component specifically binds to antigens expressed on the surface of target cells, facilitating the internalization of the IT. Once inside the cell, the cytotoxic agent is released, disrupting essential cellular processes and leading to cell death. This targeted approach minimizes damage to healthy tissues while effectively eliminating diseased cells. The production of ITs involves two primary methods: recombinant fusion and chemical conjugation. In recombinant fusion, genetic engineering is used to create a fusion protein that combines the antibody and toxin, ensuring precise control over their ratio and functionality. In chemical conjugation, pre-existing antibodies are chemically linked to toxins, allowing for greater flexibility in combining different antibodies and cytotoxic agents. Each method has its advantages and challenges, influencing the specificity, production complexity, and therapeutic potential of the resulting ITs. As research advances, ITs continue to show promise not only in oncology but also in treating other diseases, including inflammatory conditions and atherosclerosis. The precise targeting and potent effects of ITs make them a valuable tool in the development of new therapeutic strategies.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How mitochondrial dynamics imbalance affects the progression of breast cancer:a mini review. 线粒体动力学失衡如何影响乳腺癌的进展：微型综述。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-09-01 DOI: 10.1007/s12032-024-02479-2

Jingwen Kuang, Hao Liu, Linlin Feng, Yuan Xue, Huiyi Tang, Pengcheng Xu

引用次数: 0

Letter to the editor: comment on "Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment". 致编辑的信：关于 "益生菌衍生银纳米粒子靶向 mTOR/MMP-9/BCL-2/dependent AMPK 激活用于肝癌治疗 "的评论。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-30 DOI: 10.1007/s12032-024-02487-2

Murali Santhoshkumar

引用次数: 0

The treatment landscape of triple-negative breast cancer. 三阴性乳腺癌的治疗前景。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-29 DOI: 10.1007/s12032-024-02456-9

Yi Hu, Chen Wang, Huishi Liang, Jie Li, Qiong Yang

引用次数: 0